Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 1999

View Archived Issues

York Medical: Annual Report 1998

U.S. patent issues to Washington University for mammaglobin

Steroidogenesis Inhibitors to begin satellite open clinical studies in multiple indications

Synvisc relieves pain, delays need for total knee replacement in osteoarthritis

Cubist enters agreement with Novartis for antiinfective drug discovery

Pierre Fabre Dermatologie to commercialize Allergan's Zorac in Europe

Positive preclinical results for NuChem's anticancer compounds in lung cancer model

InSite Vision updates shareholders

PSP94 suppresses prostate cancer growth in mouse model

Rosetta and Acacia announce intention to merge

Abbott makes milestone payments to Aronex for antifungal drug Nyotran

Orally bioavailable tachykinin antagonists from MS&D for emesis, etc.

Biota's flu drug gets first approval

Astra describes N-type neuronal calcium channel blockers and their use

Good safety, increased immunogenicity reported for MF59-adjuvanted flu vaccine

Neurogen and Pfizer collaborate on development of NPY receptor ligands

New antiinflammatory/immunomodulatory compounds from Signal act at a transcriptional level

New compounds from Novo Nordisk for pain, inflammation, diabetes

Kanebo to be acquired by Organon, merged into Nippon Organon

Mitsubishi antidepressant to be codeveloped by Taisho

Glaxo presents new NNRTI from quinoxaline class that has progressed to human trials

T-140, a potent CXCR4-dependent inhibitor of HIV infection

Pediatric study supports use of vCP205 in infants born to HIV-positive mothers

Bristol-Myers Squibb suspends clinical studies of lobucavir

Celebrex receives approval in Mexico

Broad patent issues for Avigen's AAV vectors

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026